OHSS Prevention — Modern Protocols Make Severe OHSS Avoidable

Ovarian Hyperstimulation Syndrome (OHSS) is the most serious avoidable complication of IVF stimulation. Modern antagonist protocols with agonist trigger and freeze-all strategy have made severe OHSS rare. This page explains the risk factors, prevention strategy and management.

1. What OHSS is

An exaggerated response to ovarian stimulation. Multiple follicles develop simultaneously. After trigger and ovulation, the corpus luteum produces excessive VEGF (vascular endothelial growth factor), causing increased vascular permeability. Fluid shifts from blood into the abdomen and other spaces. Mild forms: bloating, discomfort. Severe forms: ascites, dehydration, thrombosis, respiratory compromise.

2. Severity grading

Mild — bloating, mild abdominal discomfort, ovaries enlarged 5–10 cm. Moderate — ascites on ultrasound, weight gain, more significant discomfort. Severe — clinical ascites, weight gain over 1 kg/day, decreased urine output, dehydration, abnormal blood tests. Critical — respiratory distress, renal failure, thrombosis, requiring intensive care.

3. Risk factors

PCOS — highest risk group. Young age. High AMH (above 3.5 ng/ml). High antral follicle count. Previous OHSS. Aggressive stimulation. hCG trigger. Pregnancy (hCG from placenta sustains OHSS). Lean body type. Many follicles developing (over 15–20). Rapid estradiol rise during stimulation.

4. Prevention — antagonist with agonist trigger

The single most important advance. Antagonist protocol allows use of GnRH agonist trigger (Lupride single dose) instead of hCG. Agonist trigger has very short half-life — induces final maturation but does not sustain corpus luteum. Severe OHSS becomes extremely rare with this approach. Standard for any OHSS-prone patient.

5. Freeze-all strategy

When agonist trigger is used, fresh embryo transfer is not optimal (luteal support insufficient). Solution: freeze all embryos, transfer in subsequent cycle with optimised endometrial preparation. Removes pregnancy from equation — prevents pregnancy-related OHSS exacerbation. Outcomes comparable to fresh transfer with much lower OHSS risk.

6. Other prevention measures

Individualised FSH dosing based on AMH and AFC — avoid over-stimulation. Lower starting doses in PCOS and high responders. Cabergoline 0.5 mg daily from trigger day for 7 days — reduces VEGF effect. Coasting (withholding FSH) in selected cases. Cycle cancellation if extreme response. Volume expansion (hydration) at retrieval.

7. Management of mild-moderate OHSS

Outpatient management. Adequate hydration. Avoid strenuous activity. Daily weight and abdominal girth monitoring. Diet — high protein, electrolyte balance. Monitor for severe symptoms. Most resolve within 1–2 weeks. Pregnancy may prolong; avoid fresh transfer if at moderate-severe risk.

8. Management of severe OHSS

Hospital admission required. IV fluid management. Albumin infusion. Thromboprophylaxis (low-molecular-weight heparin). Paracentesis for tense ascites. Monitor renal and respiratory function. Pregnancy from current cycle exacerbates and prolongs — freeze-all decision protects from this. Critical OHSS requires ICU. With modern prevention, severe OHSS is now rare.

Frequently Asked Questions

Dr. Priyadatt Patel

Senior Gynecologist · Advanced Laparoscopic Surgeon · IVF and Endometriosis Programme Lead

MS OBGyn · Pregnancy Care · Advanced Gynaecological Ultrasound · Fertility Preservation

ESHRE / ESGE / AAGL / ASRM guideline-aligned practice. 3D Karl Storz precision technique. Fertility-preservation-first philosophy. Evidence-based decisions, honest counselling, long-term outcomes orientation.